142 related articles for article (PubMed ID: 1760819)
1. Importance in timing of cyclophosphamide on the enhancement of interleukin-2-induced cytolysis.
Katsanis E; Bausero MA; Ochoa AC; Loeffler CM; Blazar BR; Leonard AS; Anderson PM
Cancer Immunol Immunother; 1991; 34(2):74-8. PubMed ID: 1760819
[TBL] [Abstract][Full Text] [Related]
2. Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide.
Hosokawa M; Sawamura Y; Morikage T; Okada F; Xu ZY; Morikawa K; Itoh K; Kobayashi H
Cancer Immunol Immunother; 1988; 26(3):250-6. PubMed ID: 3260132
[TBL] [Abstract][Full Text] [Related]
3. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
Naito K; Pellis NR; Kahan BD
Cancer Res; 1988 Jan; 48(1):101-8. PubMed ID: 3257158
[TBL] [Abstract][Full Text] [Related]
4. Combination chemo-immunotherapy: kinetics of in vivo and in vitro generation of natural killer cells and lymphokine-activated killer cells in the rat.
Stewart LS; Sewell HF; Thomson AW
Clin Exp Immunol; 1990 Mar; 79(3):416-23. PubMed ID: 2317946
[TBL] [Abstract][Full Text] [Related]
5. Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.
Mokyr MB; Ye QW
Cancer Res; 1985 Oct; 45(10):4932-9. PubMed ID: 4027979
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with thymosin alpha 1 potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of the Lewis lung carcinoma in mice.
Mastino A; Favalli C; Grelli S; Rasi G; Pica F; Goldstein AL; Garaci E
Int J Cancer; 1992 Feb; 50(3):493-9. PubMed ID: 1735618
[TBL] [Abstract][Full Text] [Related]
7. Enhanced antitumor immune responses of IL-2 gene-modified tumor vaccine by combination with IL-1 and low dose cyclophosphamide.
Cao X; Zhang W; Wan T; Yu Y; Tao Q; Wang J
J Exp Clin Cancer Res; 1999 Jun; 18(2):173-9. PubMed ID: 10464704
[TBL] [Abstract][Full Text] [Related]
8. Combined effects of chemotherapy and interleukin 2 in the therapy of mice with advanced pulmonary tumors.
Papa MZ; Yang JC; Vetto JT; Shiloni E; Eisenthal A; Rosenberg SA
Cancer Res; 1988 Jan; 48(1):122-9. PubMed ID: 3257159
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy-induced modulation of natural killer and lymphokine-activated killer cell activity in euthymic and athymic mice.
Gazit Z; Kedar E
Cancer Immunol Immunother; 1994 Apr; 38(4):243-52. PubMed ID: 8168119
[TBL] [Abstract][Full Text] [Related]
10. In vivo resistance of secondary antitumor immune response to cyclophosphamide: effects on T cell subsets.
Peppoloni S; Mathieson BJ; Herberman RB; Overton RW; Gorelik E
Cancer Immunol Immunother; 1987; 24(1):49-56. PubMed ID: 2949833
[TBL] [Abstract][Full Text] [Related]
11. IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: the potential role of NK cell subpopulations.
Evans R; Fuller JA; Christianson G; Krupke DM; Troutt AB
Cell Immunol; 1997 Jul; 179(1):66-73. PubMed ID: 9259773
[TBL] [Abstract][Full Text] [Related]
12. Tumor-specific chemoimmunotherapy of murine fibrosarcoma using tumor-specific transplantation antigen, cyclophosphamide, and interleukin-2.
Naito K; Nomi S; Komichi H; Ueda Y; Yamagishi H; Oka T; Pellis NR; Kahan BD
Cancer Detect Prev; 1992; 16(5-6):321-7. PubMed ID: 1361881
[TBL] [Abstract][Full Text] [Related]
13. Effects of a combination of cyclophosphamide and human recombinant interleukin 2 on pulmonary metastasis after the surgical removal of a 3-methylcholanthrene-induced primary tumor in autochthonous mice.
Hosokawa M; Yabiku T; Ikeda J; Sawamura Y; Okada F; Komatsumoto M; Tanabe T; Kobayashi H
Jpn J Cancer Res; 1988 Oct; 79(10):1147-54. PubMed ID: 3143703
[TBL] [Abstract][Full Text] [Related]
14. [Effects of pretreatment with lentinan or krestin on antitumor effector cell activities suppressed by cyclophosphamide].
Yang ZB
Hokkaido Igaku Zasshi; 1994 Jan; 69(1):137-45. PubMed ID: 8119654
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of the tumor determines the outcome of immunotherapy with interleukin-2, ABPP, and cyclophosphamide of micro- and macrometastatic intraperitoneal tumor.
Eggermont AM; Sugarbaker PH
Cancer Detect Prev; 1990; 14(4):483-90. PubMed ID: 2224911
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulation of interleukin-2 by cyclophosphamide: a phase IB trial.
Abrams JS; Eiseman JL; Melink TJ; Sridhara R; Hiponia DJ; Bell MM; Belani CP; Adler WH; Aisner J
J Immunother Emphasis Tumor Immunol; 1993 Jul; 14(1):56-64. PubMed ID: 8399071
[TBL] [Abstract][Full Text] [Related]
17. Correlation of natural killer cell activity and clearance of Cryptococcus neoformans from mice after adoptive transfer of splenic nylon wool-nonadherent cells.
Hidore MR; Murphy JW
Infect Immun; 1986 Feb; 51(2):547-55. PubMed ID: 3510981
[TBL] [Abstract][Full Text] [Related]
18. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
[TBL] [Abstract][Full Text] [Related]
19. Immune rejection of a large sarcoma following cyclophosphamide and IL-12 treatment requires both NK and NK T cells and is associated with the induction of a novel NK T cell population.
Karnbach C; Daws MR; Niemi EC; Nakamura MC
J Immunol; 2001 Sep; 167(5):2569-76. PubMed ID: 11509597
[TBL] [Abstract][Full Text] [Related]
20. Immunochemotherapy in B-16-melanoma-cell-transplanted mice with combinations of interleukin-2, cyclophosphamide, and PSK.
Ueno Y; Kohgo Y; Sakamaki S; Itoh Y; Takahashi M; Hirayama Y; Niitsu Y
Oncology; 1994; 51(3):296-302. PubMed ID: 8196915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]